Corneal Edema- Market Insights, Epidemiology, and Market Forecast-2034
United Kingdom, and Japan.
Identifying upcoming solid players in the market will help devise strategies to help get ahead of competitors.
Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
Highlights of Access and Reimbursement policies for retinal vein occlusion, barriers to accessibility of approved therapy, and patient assistance programs.
To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
- 1. Key Insights
- 2. Report Introduction
- 3. Corneal Edema Market Overview At A Glance
- 3.1. Market Share (%) Distribution By Therapies Of Corneal Edema In 2020
- 3.2. Market Share (%) Distribution By Therapies Of Corneal Edema In 2034
- 4. Epidemiology And Market Methodology Of Corneal Edema
- 5. Executive Summary Of Corneal Edema
- 6. Key Events
- 7. Corneal Edema: Disease Background And Overview
- 7.1. Introduction
- 7.2. Etiology
- 7.3. Pathophysiology
- 7.4. Diagnosis
- 7.4.1. Differential Diagnosis
- 7.4.2. Diagnostic Algorithm
- 7.4.3. Diagnostic Guidelines
- 7.4.3.1. American Academy Of Ophthalmology (Aao) 2018 Guideline For Corneal Edema And Opacification Preferred Practice Pattern
- 7.5. Management
- 7.5.1. Treatment Algorithm
- 7.5.2. Treatment Guidelines
- 7.5.2.1. Aao 2018 Guideline For Corneal Edema And Opacification Preferred Practice Pattern
- 8. Epidemiology And Patient Population
- 8.1. Key Findings
- 8.2. Assumptions And Rationale
- 8.2.1. Etiology-specific Diagnosed Prevalent Cases Of Corneal Edema
- 8.3. The United States
- 8.3.1. Total Diagnosed Prevalent Cases Of Corneal Edema In The Us
- 8.3.2. Etiology-specific Diagnosed Prevalent Cases Of Corneal Edema In The Us
- 9. Patient Journey
- 10. Emerging Drugs
- 10.1. Key Cross Competition
- 10.2. Eo2002: Emmetrope Ophthalmics Llc (“emmecell”)
- 10.2.1. Product Description
- 10.2.2. Other Development Activities
- 10.2.3. Clinical Development
- 10.2.4. Clinical Trial Information
- 10.2.5. Safety And Efficacy
- 10.2.6. Product Profile
- 10.2.7. Analysts’ Views
- 10.3. Tthx1114: Trefoil Therapeutics
- 10.3.1. Product Description
- 10.3.2. Other Developmental Activities
- 10.3.3. Clinical Development
- 10.3.4. Clinical Trials Information
- 10.3.5. Safety And Efficacy
- 10.3.6. Product Profile
- 10.3.7. Analyst Views
- 10.4. Glanatec (Ripasudil/K-321): D. Western Therapeutics Institute (Dwti)/Kowa Ltd.
- 10.4.1. Product Description
- 10.4.2. Other Development Activities
- 10.4.3. Clinical Development
- 10.4.4. Clinical Trial Information
- 10.4.5. Product Profile
- 10.4.6. Analysts’ Views
- 10.5. Stn1010904 (Sirolimus)/Ae001: Santen Pharmaceutical/ Actual Eyes
- 10.5.1. Product Description
- 10.5.2. Other Developmental Activities
- 10.5.3. Clinical Development
- 10.5.4. Clinical Trials Information
- 10.5.5. Product Profile
- 10.5.6. Analyst Views
- 11. Corneal Edema: Market Analysis
- 11.1. Key Findings
- 11.2. Market Outlook
- 11.3. Conjoint Analysis
- 11.4. Key Market Forecast Assumptions
- 11.5. Total Market Size Of Corneal Edema In The Us
- 11.6. Market Size Of Corneal Edema By Therapies In The Us
- 12. Key Opinion Leaders’ Views
- 13. Swot Analysis
- 14. Unmet Needs
- 15. Market Access And Reimbursement
- 15.1. The United States
- 15.1.1. Center For Medicare And Medicaid Services (Cms)
- 16. Appendix
- 16.1. Bibliography
- 16.2. Acronyms And Abbreviations
- 16.3. Report Methodology
- 17. Delveinsight Capabilities
- 18. Disclaimer
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook